𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound

✍ Scribed by Humeyra Bozoglan; Ulku Ergene; Levent Yoleri

Book ID
116929061
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
468 KB
Volume
45
Category
Article
ISSN
1473-0502

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 1-2 study of a farnesyltransfera
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

A randomized trial of continuous infusio
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia
✍ Yener Koc; Basak Oyan; Ayse Kars; Gulten Tekuzman; Hande Canpinar; Emin Kansu πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 2 views

## Abstract Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML). The objective of this randomized study was to evaluate the impact of mode of administration of MTZ on the response and recurrence rates in newly diagnosed patients wi